Search
mRNA-3351
go.drugbank.com/drugs/DB17718ExperimentalmRNA-3351 is a modified mRNA encoding the UGT1A1 gene. Developed by Moderna, it is currently being investigated as the treatment for Crigler-Najjar syndrome
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Categories: GABA-A Receptor AgonistsAUTO3
go.drugbank.com/drugs/DB17364InvestigationalIt is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
NP-6A4
go.drugbank.com/drugs/DB17599ExperimentalNP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]
Biropepimut-S
go.drugbank.com/drugs/DB14816InvestigationalBiropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral
Synonyms: MAGE-A3 trojan peptide vaccineFriulimicin B
go.drugbank.com/drugs/DB06087InvestigationalIt shows strong cidal activity against a number of Gram-positive pathogens which commonly cause serious infections in hospital patients and which are becoming more routinely acquired in the community. … Friulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.
Norgestomet
go.drugbank.com/drugs/DB11440InvestigationalVet approvedNorgestomet, also known as 11β-methyl-17-hydroxy-19-norprogesterone acetate, is a steroidal progestin used in veterinary medicine to control estrus and ovulation in cattle.
D-norleucine
go.drugbank.com/drugs/DB04419ExperimentalAn unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.
Synonyms: D-norleucine, D-(−)-norleucineEU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.